Compare SGC & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGC | NKTX |
|---|---|---|
| Founded | 1920 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.6M | 172.5M |
| IPO Year | 1994 | 2020 |
| Metric | SGC | NKTX |
|---|---|---|
| Price | $11.72 | $3.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $16.00 | $11.33 |
| AVG Volume (30 Days) | 25.3K | ★ 726.8K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.89% | N/A |
| EPS Growth | N/A | ★ 11.88 |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $566,184,000.00 | N/A |
| Revenue This Year | $3.23 | N/A |
| Revenue Next Year | $3.82 | N/A |
| P/E Ratio | $24.89 | ★ N/A |
| Revenue Growth | ★ 0.09 | N/A |
| 52 Week Low | $8.30 | $1.63 |
| 52 Week High | $13.78 | $3.49 |
| Indicator | SGC | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 76.30 | 77.89 |
| Support Level | $9.79 | $1.95 |
| Resistance Level | $13.01 | N/A |
| Average True Range (ATR) | 0.26 | 0.22 |
| MACD | 0.13 | 0.14 |
| Stochastic Oscillator | 95.40 | 93.68 |
Superior Group Of Companies Inc designs apparel products. The company operates through three segments: i) The Branded Products segment, under the brands BAMKO and HPI, produces and sells customized merchandising solutions, promotional products, and branded uniform programs. ii) The Healthcare Apparel segment, under the brands Wink and Fashion Seal Healthcare, manufactures and sells healthcare apparel including scrubs, lab coats, protective apparel, and patient garments. iii) The Contact Centers segment, through The Office Gurus entities, provides outsourced, nearshore, and onshore business process outsourcing (BPO), contact center, and call-center support services to customers in North America. The majority of the company's revenue is derived from the Branded Products segment.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.